home.social

#rarediseases — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #rarediseases, aggregated by home.social.

  1. Rare disease drugmakers seek exclusion from Medicare pricing plans

    WASHINGTON — Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #CMS #drugdevelopment #drugprices #Health #Pharmaceuticals #Policy #rarediseases #Research #STAT+ #WhiteHouse
    newsbeep.com/us/775982/

  2. Rare disease drugmakers seek exclusion from Medicare pricing plans

    WASHINGTON — Biotech companies are lobbying the Trump administration to exclude treatments for rare diseases from programs that…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #CMS #drugdevelopment #drugprices #Health #Pharmaceuticals #Policy #rarediseases #Research #STAT+ #WhiteHouse
    newsbeep.com/us/775982/

  3. ARPA-H invests $160 million to make custom gene editing routine

    ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #crispr #Geneediting #GeneTherapy #Health #hhs #rarediseases #STAT+
    newsbeep.com/us/753035/

  4. ARPA-H invests $160 million to make custom gene editing routine

    ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Healthcare #biotechnology #crispr #Geneediting #GeneTherapy #Health #hhs #rarediseases #STAT+
    newsbeep.com/us/753035/

  5. Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

    First gene replacement therapy in the EU for broad population with SMA, including children two years and older,…
    #Europe #EU #EuropeanCommission #CellandGeneTherapy #neuroscience #Novartis #rarediseases #ReimagineMedicine
    europesays.com/europe/84540/

  6. Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
    #France #FR #Europe #EU #Sanofi #antitrustinvestigation #EuropeanCommission #EuropeanEconomicArea #fluvaccine #Pompedisease #rarediseases #SimplyWallSt
    europesays.com/france/43941/

  7. Sanofi (ENXTPA:SAN) Faces EU Antitrust Probe As Nexviazyme Trial Delivers Positive Data

    Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
    #Europe #EU #antitrustinvestigation #EuropeanCommission #europeaneconomicarea #EuropeanUnion #fluvaccine #Pompedisease #rarediseases #Sanofi #SimplyWallSt
    europesays.com/europe/82995/

  8. Dangerous tick-borne virus spreading to more Americans, experts warn

    NEWYou can now listen to Fox News articles! A rare and potentially fatal tick-borne illness currently spreading across…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Health #infectiousdisease #Insects #Lifestyle #outbreaks #outdoorlivingrealestatelifestyle #rarediseases #Viruses
    newsbeep.com/us/733680/

  9. Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

    Elixirgen Therapeutics, Inc. BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company developing…
    #EuropeSays #Japan #JP #biotechnologycompany #Nippon #NipponShinyaku #rarediseases #Therapeutics
    europesays.com/japan/49112/

  10. Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

    Elixirgen Therapeutics, Inc. BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company developing…
    #EuropeSays #Japan #JP #biotechnologycompany #Nippon #NipponShinyaku #rarediseases #Therapeutics
    europesays.com/japan/47924/

  11. AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline

    astrazenica ©Shutterstock AstraZeneca plc (LSE:AZN) delivered a strong start to 2026, posting first-quarter total revenue of $15.3 billion,…
    #EuropeSays #Britain #Europe #EU #AstraZeneca #AstraZenecaPLC #earningspershare #oncologytreatments #rarediseases #Strategicpartnerships
    europesays.com/britain/55463/

  12. Sanofi unveils AI-powered platform for early rare disease detection | Company News

    The free web-based tool enables healthcare professionals to input a patient’s symptoms, medical history and test…
    #France #FR #Europe #EU #Sanofi #AccelRare #AIdiagnosistool #CentresofExcellence #healthcareai #medicaldiagnostics #MedVir #rarediseasedetection #rarediseases #SanofiIndia
    europesays.com/france/25730/

  13. 𝗥𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗺𝗮𝗻𝗱 𝗮𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁 𝗶𝘀 𝗲𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝗮 𝗵𝗶𝗴𝗵 𝗴𝗿𝗼𝘄𝘁𝗵 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗵𝗮𝘀𝗲!
    The 𝗠𝗶𝗱𝗱𝗹𝗲 𝗘𝗮𝘀𝘁 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 is expanding as governments improve healthcare access, diagnostics, and specialty drug availability. Rising awareness and advancements in personalized medicine are reshaping patient care outcomes.
    𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: kenresearch.com/middle-east-ra
    #Healthcare #RareDiseases #MiddleEast #PharmaIndustry

  14. Soligenix advances rare disease innovation using platform science to expand its therapeutic pipeline and address unmet medical needs affecting millions. #RareDiseases #Biotech

  15. Soligenix advances rare disease innovation using platform science to expand its therapeutic pipeline and address unmet medical needs affecting millions. #RareDiseases #Biotech

  16. Soligenix reports strong Phase 3 HyBryte data for cutaneous T-cell lymphoma, with response rates exceeding expectations. Interim analysis could accelerate commercialization path. #Biotech #RareDiseases

  17. Soligenix reports strong Phase 3 HyBryte data for cutaneous T-cell lymphoma, with response rates exceeding expectations. Interim analysis could accelerate commercialization path. #Biotech #RareDiseases

  18. Soligenix publishes peer-reviewed HyBryte clinical data demonstrating safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 trial interim results expected Q2 2026. #Biotech #RareDiseases

  19. Soligenix publishes peer-reviewed HyBryte clinical data demonstrating safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 trial interim results expected Q2 2026. #Biotech #RareDiseases

  20. Soligenix publishes HyBryte clinical data in peer-reviewed journal, highlighting safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 interim analysis expected Q2 2026. #Biotech #RareDiseases

  21. Soligenix publishes HyBryte clinical data in peer-reviewed journal, highlighting safety and efficacy for cutaneous T-cell lymphoma treatment. Phase 3 interim analysis expected Q2 2026. #Biotech #RareDiseases

  22. Soligenix's SGX945 receives Promising Innovative Medicine designation from UK MHRA for Behçet's disease, advancing rare disease treatment development. #Biotech #RareDiseases

  23. Soligenix's SGX945 receives Promising Innovative Medicine designation from UK MHRA for Behçet's disease, advancing rare disease treatment development. #Biotech #RareDiseases

  24. Soligenix approaches pivotal 2026 with Phase 3 HyBryte trial for CTCL and SGX945 advancement for Behçet's disease. Multiple clinical catalysts expected. #Biotech #RareDiseases

  25. Soligenix approaches pivotal 2026 with Phase 3 HyBryte trial for CTCL and SGX945 advancement for Behçet's disease. Multiple clinical catalysts expected. #Biotech #RareDiseases

  26. Soligenix enters a pivotal 2026 with key clinical milestones ahead, including Phase 3 FLASH2 trial data for HyBryte in CTCL treatment and progress on SGX945 for Behçet's disease. #Biotech #RareDiseases

  27. Soligenix enters a pivotal 2026 with key clinical milestones ahead, including Phase 3 FLASH2 trial data for HyBryte in CTCL treatment and progress on SGX945 for Behçet's disease. #Biotech #RareDiseases

  28. Soligenix receives EU orphan drug designation for dusquetide in Behçet Disease, securing 10 years of market exclusivity. Phase 2a data demonstrated efficacy and safety. #Biotech #RareDiseases

  29. Soligenix receives EU orphan drug designation for dusquetide in Behçet Disease, securing 10 years of market exclusivity. Phase 2a data demonstrated efficacy and safety. #Biotech #RareDiseases

  30. Soligenix receives EU orphan drug designation for dusquetide in Behcet Disease, securing 10 years of market exclusivity. Builds on Phase 2a efficacy data. #Biotech #RareDiseases

  31. Soligenix receives EU orphan drug designation for dusquetide in Behcet Disease, securing 10 years of market exclusivity. Builds on Phase 2a efficacy data. #Biotech #RareDiseases

  32. Soligenix advances Phase 3 FLASH2 trial for cutaneous T-cell lymphoma with interim analysis expected Q2 2026. Company also secured orphan drug designation for dusquetide in Behçet's Disease. #Biotech #RareDiseases